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Abstract 
Background 
Diabetes mellitus (DM) is rising globally yet relatively little is known about the 
characteristics and management of DM patients from low- and middle-income 
countries (LMIC).  
Methods 
We systematically characterized consecutive DM patients attending public health 
services in urban settings in Indonesia, Peru, Romania and South Africa, collecting 
data on DM treatment history, complications, drug treatment, obesity, HbA1c, and 
cardiovascular risk profile; and assessing treatment gaps against relevant national 
guidelines.   
Results 
Patients (median 59 years, 62.9% female) mostly had type 2 diabetes (96%), half for 
>5 years (48.6%). Obesity (45.5%) and central obesity (females 84.8%; males 62.7%) 
were common. The median HbA1c was 8.7% (72 mmol/mol), ranging from 7.7% (61 
mmol/mol; Peru) to 10.4% (90 mmol/mol; South Africa). Antidiabetes treatment 
included metformin (62.6%), insulin (37.8%), and other oral glucose-lowering drugs 
(34.8%). Disease complications included eyesight problems (50.4%), EGFR <60 
ml/min (18.9%), heart disease (16.5%), and proteinuria (14.7%). Many had an elevated 
cardiovascular risk with elevated blood pressure (36%), LDL (71.0%), and smoking 
(13%), but few were taking antihypertensive drugs (47.1%), statins (28.5%) and aspirin 
(30.0%) when indicated. Few patients on insulin (8.0%), statins (8.4%) and 
antihypertensives (39.5%) reached treatment targets according to national guidelines. 
There were large differences between countries in terms of disease profile and 
medication use.  
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Conclusion 
DM patients in government clinics in four LMIC with considerable growth of DM have 
insufficient glycemic control, frequent macrovascular and other complications, and 
insufficient preventive measures for cardiovascular disease. These findings underline 
the need to identify treatment barriers and secure optimal DM care in such settings. 
 
 
INTRODUCTION 
Diabetes mellitus (DM) is one of the largest global health emergencies of the 21st 
century. In 2017, there were 425 million adults estimated to be living with DM, and this 
number is predicted to increase to 629 million by 2045 (1; 2). An estimated 80% of 
people with DM live in low- or middle-income countries (LMICs) (2). Although studies 
are few, compared to individuals living in high-income countries, those with DM in LMIC 
may present at a younger age or with more advanced disease and more disease 
complications (3). Health care access and long-term care may be more problematic, 
with inadequate access to laboratory testing, medication such as insulin, health 
information, and limited self-management of patients (4). Also, people living with DM 
in tropical countries may be at higher risk for infectious diseases (5). Cardiovascular 
complications, the leading cause of mortality and morbidity among patients with type 
2 DM (6; 7), may also be more common among people living with DM in LMICs (8-10), 
due to higher rates of smoking, and lower access to cardiovascular risk assessment 
and management (11-15). Assessment of diabetes disease characteristics, 
cardiovascular risk profile and medical management of people living with DM has been 
undertaken in some country-specific studies (16-18) and compared across LMIC 
countries in Asia and sub-Saharan Africa (12; 19; 20). Such studies are needed to help 
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improve management of DM and reduce its progression and complications. 
 
As part of the TANDEM project on DM and tuberculosis (21), we have systematically 
characterized people with DM in government health clinics or hospitals in Indonesia, 
Peru, Romania and South Africa, four countries that are witnessing a rapid growth of 
DM (1). The TANDEM project has examined the prevalence of tuberculosis among 
individuals with DM, but this also allowed us to characterize DM patients in these four 
countries. Thus, the objectives of the present study were: (1) to establish disease 
phenotype and cardiovascular risk profile of DM patients; (2) to characterise medical 
treatment, and gaps between national and international guidelines and actual patient 
care as a ‘cascade of care’, and (3) to identify possible socio-demographic factors 
associated with inadequately controlled DM or with sub-optimal management. 
 
METHODS 
Setting and design 
This study is part of The Concurrent Tuberculosis and Diabetes Mellitus (TANDEM) 
study which aims to develop methods for better screening and management of 
combined tuberculosis and DM, and to increase basic knowledge about the link 
between the two diseases (21). TANDEM is a multicentre prospective study with field 
sites in Peru, Romania, South Africa and Indonesia, countries with diverse healthcare 
systems and population demographics, but all with a relatively high burden of 
tuberculosis and an increasing prevalence of DM (1; 22). The TANDEM study recruited 
2096 consecutive patients (December 2013 to June 2016) with previously diagnosed 
DM to be screened for tuberculosis through symptom screen, chest X-ray and sputum 
examination. To identify possible factors associated with tuberculosis, all patients were 
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uniformly and systematically characterized in terms of DM disease characteristics and 
management. These data were used for the current study, excluding those patients in 
whom active tuberculosis was diagnosed.  
 
In Indonesia, DM patients were recruited in 25 community health centres and from the 
endocrine clinic in a tertiary public referral hospital in Bandung. In Peru, patients were 
recruited at a diabetes clinic at one tertiary level public hospital in Lima, as diabetes 
care in the public domain is mainly provided by hospitals. In Romania, patients with 
DM were recruited from two secondary level hospitals in Craiova. In South Africa, 
patients were recruited at three community health centres in the northern Cape Town 
metropolitan area. For more details of study site selection and location see 
Supplementary File. 
 
Study procedures  
Patients with known DM (either under care for DM or on DM medication) who were 
above 18 years of age were eligible; those with gestational or steroid induced diabetes 
were excluded. Following provision of written informed consent, research doctors 
conducted an interview, using a validated questionnaire, with each patient asking 
about their socio-demographic characteristics (age, gender, and education, and assets 
to link to socio-economic status), behavioural characteristics such as self-reported 
smoking status and alcohol consumption, and diabetes characteristics such as DM 
history, complications, medication, and management. Research nurses followed a 
standard operating procedure for taking patients’ blood pressure using a digital device, 
and for measuring height, weight (using digital scales), and waist measurement for 
calculation of body mass index (BMI) and central obesity. Venous blood was taken for 
laboratory glycated hemoglobin (HbA1c), and urine for albumin to creatinine ratio 
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(ACR). All HbA1c samples were analysed in an accredited laboratory with NGSP 
certification, using the HPLC methods according to WHO guidelines and with DCCT 
aligned assays. Lipid profile and creatinine, recorded as the most recent test 
undertaken within the previous month, was obtained from the medical records for a 
sub-set of patients. Laboratory methods for both LDL and HDL used Siemens 
dimension clinical chemistry system. Ethical approval was received from the 
Observational/Interventions Research Ethics Committee, London School of Hygiene 
and Tropical Medicine on 18 December 2013 (LSHTM ethics ref: 6449, LSHTM 
amendment no: A473) and Institutional Review Boards in Indonesia, Romania, Peru 
and South Africa. 
 
Data management and variables used 
Demographic and clinical data were entered onto a case report form and then into a 
secure, centrally managed, electronic database (REDCap). Other data, such as 
laboratory results, diabetes history, smoking status and complications were entered 
directly into REDCap. Data quality was checked on a monthly basis for accuracy and 
completeness.  
Blood pressure was categorised according to the JNC VIII (23):  Normal (systolic and 
diastolic <120/80 mmHg); Pre-hypertension (systolic 120-139 or diastolic 80-89 
mmHg); Stage I hypertension  (systolic 140-159 or diastolic 90-99 mmHg); Stage II 
hypertension (systolic ≥160 or diastolic ≥100 mmHg). Weight and height for Indonesian 
patients were classified based on the Asia Pacific Criteria of Body Mass Index (24): 
Under-weight (<18·5 kg/m2); Normal (18·5-22·9 kg/m2); Over-weight (23·0-24·9 
kg/m2); Obese I (25·0-29·9 kg/m2); Obese II (≥30 kg/m2). Weight and height for the 
three other sites were classified according to the World Health Organization (25): 
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Under-weight (<18·5 kg/m2); Normal (18·5-24·9 kg/m2); Over-weight (25·0-29·9 
kg/m2); Obese (≥30 kg/m2). Central obesity for female patients in all sites was 
categorized as a waist circumference (WC) of ≥80 cm. Central obesity for males was 
categorized as a WC ≥90 cm for Indonesia and Peru and ≥94cm for Romania and 
South Africa (26). Laboratory HbA1c was categorised into three groups <7·0; 7·0-9·9; 
≥10% (<53; 53-85; ≥86 mmol/mol) for analysis (27). ACR categories were normal (<30 
ug/mg); moderately increased (30-299 ug/mg), and albuminuria (≥300 ug/mg). Low-
density lipoprotein (LDL) were categorized as dyslipidemia if the result was ≥100 
mg/dL (2.6 mmol/l), or if high-density lipoprotein (HDL) was ≤40 mg/dL (1.0 mmol/l) for 
males or ≤50 mg/dL (≤1.3 mmol/l) for females (27; 28). Estimated glomerular filtration 
rate (eGFR) was calculated according to the CKD-EPI creatinine equation 2009 (29). 
Principal Component Analysis (30) was performed to build a socio-economic status 
index based on asset ownership by patients that included non-sellable (possession of 
a bank account, type of sanitation facility, household water source) and sellable assets 
(e.g. stove, refrigerator, washing machine, television).   
 
Diabetes mellitus treatment guidelines for the four countries 
The gap between optimal and actual treatment with insulin, antihypertensive, lipid-
lowering and antiplatelet drugs was calculated using patient’s HbA1c, blood pressure, 
LDL and cardiovascular (coronary artery disease, myocardial infarction, angina) 
disease history. Among patients using insulin, antihypertensive and lipid-lowering 
drugs, HbA1c, blood pressure and LDL values were used to examine what proportion 
of patients reached desired treatment targets according to national guidelines (19; 27; 
28; 31; 32): 
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1. Patients with HbA1c ≥10% (86 mmol/mol) should have insulin added to their 
medications. 
2. Patients with blood pressure ≥140 systolic or ≥90 diastolic should be managed 
with anti-hypertensive medication. 
3. Cardiovascular complications should be managed with aspirin. 
Macrovascular complications included infarct (coronary artery disease, angina, 
myocardial infarction), heart failure, cerebrovascular disease, peripheral vascular 
disease). Microvascular complications included a history of renal disease, neuropathy, 
eye problems (blindness, impaired vision, glaucoma, cataract).  
 
Statistical analysis 
Descriptive data are presented as mean and standard deviation for normally distributed 
data, median and inter-quartile range (IQR) for non-normally distributed data, and 
proportions for categorical data. Odds ratios and 95% confidence intervals were 
estimated using logistic regression to investigate factors associated with severe 
disease (defined as an HbA1c ≥10% (86 mmol/mol) or macrovascular or microvascular 
complications) and poor medical treatment (defined as patients not receiving insulin, 
anti-hypertensives or aspirin when it is indicated). We then undertook multiple logistic 
regression, including all the variables in the model. A test for trend was done for ordinal 
variables where the trend was consistent but no individual levels were statistically 
significant. Univariate and multivariate analysis was not undertaken for South Africa 
due to the small number of participants. All analyses were stratified by site, given the 
substantial heterogeneity expected. Statistical analyses were performed using STATA 
Version 12·1. 
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RESULTS 
General patient characteristics 
After excluding 28 DM patients with active tuberculosis, 2068 were included, in 
Indonesia (n=783), Peru (n=599), Romania (n=603), and South Africa (n=83). Baseline 
characteristics are shown in Table 1. All patients in Peru and South Africa had type 2 
DM, 98% in Indonesia and 87% in Romania. Almost half of the patients (49%) had had 
DM for at least five years. Their median age was 59 years, 63% were female and 33% 
had an education of primary school or less.  
 
Glycemic control and diabetes complications  
The median HbA1c across all four sites was 8·7% (IQR 7·0-10·7%) (72; 53-93 
mmol/mol). It was highest in South Africa (10·4%; 90 mmol/mol) and appeared lowest 
in Peru (7·7%; 61 mmol/mol), although HbA1c was missing for a substantial proportion 
of DM patients in Peru (Table 1; Supplementary Figure 1). The proportion of patients 
using metformin was 63% overall, with the greatest use in South Africa (90%), and the 
lowest in Indonesia (55%). Insulin, either alone or in combination with oral medication, 
was used by 38% of patients overall, with the highest use of insulin in Romania (67%) 
where patients were recruited in hospital wards, and the lowest in Peru (20%) (Table 
1). Disease complications including heart disease, eyesight problems, micro- and 
macroalbuminuria, and decreased renal clearance were common across all 
populations (Table 1).  
 
Cardiovascular risk profile 
On average, patients had a moderately increased cardiovascular risk profile, as shown 
in Table 2. Overall, almost half of the DM patients had a BMI categorised as obese 
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(46%). This was highest for the Indonesian cohort when using the Asia Pacific Criteria 
of BMI (Obese I, 39·3%; Obese II, 14·2%). Eighty-five percent of females and 63% of 
males across sites were categorised as having central obesity. Uncontrolled 
hypertension in patients not on anti-hypertensives, was reported in 36% of the overall 
cohort and this was highest in South African patients (52%) and lowest in patients in 
the Peru site (15%). Current smoking was reported in 13% of patients across all sites. 
In a subset of patients in three sites, dyslipidemia (LDL ≥100 mg/dL (2.6 mmol/l)), for 
patients not on statins, was reported in 74% (Indonesia 80%; Romania 55%; South 
Africa 52%).  
 
Medical treatment 
Uptake of treatment and success in terms of reaching treatment targets was 
suboptimal, with large variation between sites. For instance, of patients with an 
indication for insulin (HbA1c ≥10%, 86 mmol/mol),  55% were using insulin, varying 
from 80% in Romania, to 73% in South Africa, 41% in Peru, and 32% in Indonesia 
(Table 3). Of patients in these sites who were on insulin, only a small proportion had 
their HbA1c controlled to <7% (53 mmol/mol) (Table 4). Similarly, of 913 patients with 
hypertension, less than half (47%) were taking antihypertensive drugs (Table 3), while 
only 40% of 711 patients taking anti-hypertensive drugs had their blood pressure 
controlled (Table 4). Of 326 patients reporting cardiovascular complications, 30% were 
on aspirin, ranging from 86% in South Africa to 20% in Indonesia (Table 3). Blood 
lipids were only available for a subset of patients, and not for patients in Peru. Of 267 
patients with dyslipidemia (LDL ≥100 mg/dL (2.6 mmol/l)), 29% were treated with 
statins (Table 3). Of 407 patients who were taking statin medication, only 8% had a 
LDL level of less than 100 mg/dL (2.6 mmol/l) (Table 4). 
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Factors associated with disease severity and medical treatment 
Disease severity and medical treatment and underlying factors differed substantially 
between countries. We assessed risk factors for disease severity as defined separately 
by a high HbA1c, macrovascular or microvascular complications (Supplementary 
Tables S1-3). Older age was associated with macrovascular complications in 
Indonesia (OR 1.50; 95% CI 1.02-2.20) and Romania (OR 2.52; 95% CI 1.65-3.87) but 
not in Peru (OR 1.41; 95% CI 0.74-2.69), and with lower HbA1c in Indonesia (OR 0.45; 
95% CI 0.32-0.64), but not in Romania (OR 0.83; 95% CI 0.57-1.21) or Peru (OR 0.61; 
95% CI 0.35-1.06). Males were more likely to have macrovascular complications in 
Indonesia (OR 1.81; 95% CI 1.24-2.63). Longer DM duration was associated with more 
macro- and microvascular complications in Romania (6-15 years: OR 2.59; 95% CI 
1.35-4.99, and OR 2.11; 95% CI 1.33-3.37, respectively; >15 years DM duration: OR 
4.23; 95%CI 2.09-8.55, and OR 7.06; 95% CI 3.81-13.07, respectively), and with more 
microvascular complications in Indonesia (6-15 years: OR 1.75; 95% CI 1.09-2.81; >15 
years: OR 3.72; 95% CI 1.94-7.13) and Peru (>15 years: OR 2.07; 95% CI 1.02-4.18). 
Completed high school education and Q3 socioeconomic status were associated with 
lower HbA1c in Romania (OR 0.43; 95% CI 0.24-0.79 and OR 0.56; 95% CI 0.33-0.97, 
respectively). Completed high school education was associated with less 
microvascular complications in Peru (OR 0.44; 95% CI 0.27-0.73) and Romania (OR 
0.43; 95% CI 0.23-0.80), but not Indonesia (OR 1.08; 95% CI 0.71-1.66).  
We assessed what factors were associated with non-compliance to treatment 
guidelines with regard to use of insulin, anti-hypertensives and aspirin (Supplementary 
Tables S4-6). Compared to females, males were more likely to take insulin in Indonesia 
(OR 2.26; 95% CI 1.16-4.42), but less likely to take anti-hypertensives when indicated 
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(OR 0.43; 95% CI 0.26-0.70). Older aged patients were more likely to be taking anti-
hypertensives in Indonesia (OR 2.29; 95% CI 1.44-3.62), but were less likely to be 
taking aspirin for cardiovascular complications in Romania (OR 0.34; 95% CI 0.13-
0.86). DM duration of 6-15 years was associated with increased likelihood of taking 
insulin in Indonesia (OR 2.70; 95% CI 1.05-6.96) and Romania (OR 2.35; 95% CI 1.09-
5.03), and of taking anti-hypertensives in Peru (OR 5.73; 95% CI 1.30-25.13). No 
significant associations were found between education or socioeconomic status.  
 
DISCUSSION 
Numerous studies have addressed the growing burden of diabetes in low- and middle- 
income countries but detailed patient data like disease complications and specific drug 
treatment have mostly been reported in single-site studies. In the context of the 
TANDEM project on the interaction between diabetes and tuberculosis (21), we have 
pooled systematically collected detailed characteristics of more than 2000 DM patients 
from Indonesia, Peru, Romania and South Africa. Three main conclusions could be 
drawn. First, both among hospitalised and ambulatory patients in these four countries, 
glycemic control is often poor, disease complications are common, and the 
cardiovascular risk is often high. Second, across different settings many patients who 
qualify for insulin, anti-hypertensive, lipid-lowering drugs or aspirin do not receive these 
drugs. Third, of those on these drugs, only a minority reach desired treatment targets. 
These findings underline the need to identify treatment barriers and secure optimal DM 
care in low- and middle-income countries where most people with DM live. 
 
Recent studies have addressed the ‘cascade of care’ for diabetes (19; 20; 33). For 
instance, based on population surveys in 12 sub-Saharan African countries it was 
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estimated that only 37% of DM patients were aware of their diagnosis, and only 11% 
received medication (19). But these studies have also stressed the lack of data 
regarding the burden of diabetes-related complications. Systematically collecting data 
from individual patients we could precisely characterize disease severity, 
complications and drug treatment. With regard to disease severity, hyperglycemia was 
common yet use of insulin was low. Poor glycemic control in Romania could be due to 
a selection bias as only in-patients were investigated, who are more likely to have poor 
disease management or infections or other disease complications leading to 
hyperglycemia. Among ambulatory patients in the others sites the proportion of 
patients with an HbA1c <7% (53 mmol/mol) ranged from 11% to 28%. Moreover, from 
discussion with local practitioners and evaluation of patient records it became clear 
that HbA1c was not routinely measured, and in Peru even during this study it proved 
impossible in a large proportion of patients due to the local unavailability of HbA1c 
tests. Lack of HbA1c monitoring probably contributes to poor glycemic control. Other 
factors include insufficient or inadequate use of insulin, which is often not available 
(34), too expensive, or difficult to use because of patients unwillingness or inability to 
do self-monitoring of blood glucose (35). Even metformin and sulphonylurea derivates, 
widely used and cheap diabetes drugs, are often not available or prohibitively 
expensive (36; 37).  
 
Like poor glycemic control, disease complications as reported in other studies (7; 9; 
38; 39), were common, with many patients suffering from cardiovascular disease, 
eyesight problems and renal disease. Local health providers may not be fully aware of 
disease severity of their patients, because time and resources are often lacking to 
conduct systematic assessment (14; 40), as was done in this study. Our study may 
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even underestimate the proportion of patients with disease complications as we mainly 
relied on patient history and medical records and did not perform electrocardiography, 
fundoscopy, or other related tests. Our cross-sectional study was unable to establish 
what proportion of complications were already present at the time of initial 
presentation, and how often complications develop while patients are under DM care, 
as a result of insufficient glycemic control and cardiovascular risk management. It is 
clear that both earlier detection of DM and better glycemic control and cardiovascular 
risk management are needed.  
 
Cardiovascular risk profile was elevated in most patients. Obesity, uncontrolled 
hypertension and dyslipidemia were common. The proportion of patients smoking was 
less than we had expected, ranging from 6% in Peru, 14% in Indonesia, 16% in 
Romania and 37% in South Africa. It is possible that patients may have given socially-
desirable answers, particularly as a much higher proportion reported having stopped 
smoking in most sites. Also, in these countries, smoking is more common among men, 
while almost two-thirds of study patients were female. 
 
We found large discrepancies between guidelines and practice regarding use of insulin 
and cardiovascular risk management. Approximately half of those patients qualifying 
for insulin or antihypertensive drugs received these drugs. Similarly, of those with an 
indication for statins, or aspirin as secondary prevention of cardiovascular disease, 
only 30% were prescribed these drugs. And of those who were prescribed these drugs, 
targets in terms of HbA1c, blood pressure and LDL were only met for 8%, 40%, and 
8% respectively. This could be due to incomplete treatment adherence, which was not 
assessed in this study, or insufficient dosing. Optimal glycemic control with insulin is 
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difficult to achieve without self-monitoring of blood glucose, but this is not routine in 
government clinics in any of the four sites. Similary, self-measurement of blood 
pressure is rarely done, and blood pressure is not measured at each clinic. Limited 
time and space in clinics, or low awareness or lack of training among health 
professionals may contribute to the poor ‘cascade of care’ in DM care in low-resource 
settings (14; 38; 40; 41). 
 
This study suffers from limitations. As it was a cross-sectional study of patients who 
had had DM for a median of 5 years or more we do not know how many patients 
present with complications, and how many patients die from DM over time or 
disengage from DM care. Second, it is unlikely that our data are fully representative of 
the four countries. Assessment of the DM phenotype and treatment was not a primary 
objective of TANDEM, and patients were only recruited in a limited number of clinics. 
In Romania, we only included inpatients, who likely suffer from poorer glycemic control 
and more disease complications. Third, complications were mostly self-reported. It 
would have been preferable to have a formal assessment by a cardiologist, neurologist 
and eye physician but this was beyond the scope of this study. Fourth, for some 
characteristics there was a lot of missing data. For instance, recent lipid 
measurements, not included in the TANDEM assessment, but extracted from patient 
records, were not available in Peru, and only in a minority of patients from the other 
sites, and HbA1c was often missing in Peru and South Africa most likely due to 
frequent unavailability of laboratory tests. Lack of coverage from public health 
insurance or unawareness among health professionals may also be involved.  
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Despite these limitations we feel that our study, using a standardised method and 
addressing the most important disease and treatment characteristics, shows a clear 
picture of the severity of DM in these countries across four continents and of the unmet 
needs in terms of drug treatment. Future studies should examine these issues 
longitundinally, identify barriers to optimal DM care, and evaluate possible 
interventions to help improve the outcome of DM patients.  
 
Acknowledgements: 
Funding: 
This work was supported by the TANDEM project, which is funded by the European 
Union’s Seventh Framework Programme (FP7/2007–2013) under Grant Agreement 
Number 305279. 
Competing Interests: 
The authors declare that no competing interests exist. 
Author contributions: 
RvC and NS conceived the idea and developed the analysis plan with input from SM 
and JC. SM performed the main statistical analyses with input from FP, SKB, YL and 
JC. NS and SM drafted the paper. All other authors contributed to the development of 
the overall project, data collection and manuscript writing. All authors approved the 
final version of the manuscript.  
  
 17 
REFERENCES 
1. IDF Diabetes Atlas [article online], 2017. Available from 
www.diabetesatlas.org/resources/2017-atlas.html. Accessed 4 December 2017  
2. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century 
challenge. Lancet Diabetes Endocrinol 2014;2:56-64 
3. Misra A, Tandon N, Ebrahim S, Sattar N, Alam D, Shrivastava U, Narayan KM, 
Jafar TH. Diabetes, cardiovascular disease, and chronic kidney disease in South 
Asia: current status and future directions. BMJ 2017;357:j1420 
4. Phillimore P, Zaman S, Ahmad B, et al. Health system challenges of 
cardiovascular disease and diabetes in four Eastern Mediterranean countries. Global 
Public Health 2013;8:875-889 
5. van Crevel R, van de Vijver S, Moore DA. The global diabetes epidemic: what 
does it mean for infectious diseases in tropical countries? Lancet Diabetes 
Endocrinol 2016;5:457-468 
6. Leon BM, Maddox TM. Diabetes and cardiovascular disease: Epidemiology, 
biological mechanisms, treatment recommendations and future research. World J 
Diabetes 2015;6:1246-1258 
7. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes 
mellitus and its complications. Nat Rev Endocrinol 2018;14:88-98 
8. Lim SS, Gaziano TA, Gakidou E, Reddy KS, Farzadfar F, Lozano R, Rodgers A. 
Prevention of cardiovascular disease in high-risk individuals in low-income and 
middle-income countries: health effects and costs. The Lancet 2007;370:2054-2062 
9. Unnikrishnan R, Anjana RM, Mohan V. Diabetes mellitus and its complications in 
India. Nat Rev Endocrinol 2016;12:357-370 
10. Gupta R, Misra A. Epidemiology of microvascular complications of diabetes in 
South Asians and comparison with other ethnicities. J Diabetes 2016;8:470-482 
11. Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing 
epidemic of coronary heart disease in low- and middle-income countries. Curr Probl 
Cardiol 2010;35:72-115 
12. Yeung RO, Zhang Y, Luk A, et al. Metabolic profiles and treatment gaps in 
young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study 
of a prospective cohort. Lancet Diabetes Endocrinol 2014;2:935-943 
13. Luk AO, Li X, Zhang Y, et al. Quality of care in patients with diabetic kidney 
disease in Asia: The Joint Asia Diabetes Evaluation (JADE) Registry. Diabet Med 
2016;33:1230-1239 
14. Attaei MW, Khatib R, McKee M, et al. Availability and affordability of blood 
pressure-lowering medicines and the effect on blood pressure control in high-income, 
middle-income, and low-income countries: an analysis of the PURE study data. 
Lancet Public health 2017;2:e411-e419 
15. Murphy A, Palafox B, O'Donnell O, et al. Inequalities in the use of secondary 
prevention of cardiovascular disease by socioeconomic status: evidence from the 
PURE observational study. Lancet Global health 2018;6:e292-e301 
16. Mohan V, Shah SN, Joshi SR, et al. On behalf of the DiabCare India Study 
Group. Current status of management, control, complications and psychosocial 
aspects of patients with diabetes in India: Results from the DiabCare India 2011 
Study. Indian J Endocrinol Metab 2014;18:370-378 
17. Omar MS, Khudada K, Safarini S, Mehanna S, Nafach J. DiabCare survey of 
diabetes management and complications in the Gulf countries. Indian J Endocrinol 
Metab 2016;20:219-227 
 18 
18. Mafauzy M, Zanariah H, Nazeri A, Chan SP. DiabCare 2013: A cross-sectional 
study of hospital based diabetes care delivery and prevention of diabetes related 
complications in Malaysia. Medical J Malaysia 2016;71:177-185 
19. Atun R, Davies JI, Gale EAM, et al. Diabetes in sub-Saharan Africa: from clinical 
care to health policy. Lancet Diabetes Endocrinol 2017;5:622-667 
20. Manne-Goehler J, Atun R, Stokes A, et al. Diabetes diagnosis and care in sub-
Saharan Africa: pooled analysis of individual data from 12 countries. Lancet Diabetes 
Endocrinol 2016;4:903-912 
21. van Crevel R, Dockrell H. TANDEM: Understanding diabetes and tuberculosis. 
Lancet Diabetes Endocrinol 2014;2:270-272 
22. World Health Organization. Global tuberculosis report.  Geneva, World Health 
Organization, 2017 
23. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the 
management of high blood pressure in adults: Report from the panel members 
appointed to the eighth joint national committee (jnc 8). JAMA 2014;311:507-520 
24. Yoon K-H, Lee J-H, Kim J-W, et al. Epidemic obesity and type 2 diabetes in Asia. 
Lancet 2006;368:1681-1688 
25. World Health Organization: Waist circumference and waist–hip ratio: report of a 
WHO expert consultation, Geneva, 8-11 December 2008.  Geneva, World Health 
Organization, 2008 
26. International Diabetes Federation. The IDF consensus worldwide definition of the 
Metabolic Syndrome.  Brussels, Belgium, International Diabetes Federation, 2006 
27. American Diabetes Association. Standards of medical care in diabetes - 2016 J 
Clin App Res Ed 2016;39:S1-S2 
28. Indonesia Endocrinology Society. Konsensus Pengelolaan dan Pencegahan 
Diabetes Melitus Tipe 2 di Indonesia. 2015 
29. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular 
filtration rate. Ann Int Med 2009;150:604-612 
30. Vyas S, Kumaranayake L. Constructing socio-economic status indices: how to 
use principal components analysis. Health Policy Plan 2006;21:459-468 
31.  Ghid medical pentru îngrijirea pacienţilor cu diabet zaharat (Medical guideline for 
the management of patients with diabetes mellitus) [article online], 2016. Available 
from https://legeaz.net/monitorul-oficial-179-2016/oms-226-2016-ghiduri-practica-
medicala/ghid-medical-pentru-ingrijirea-pacientilor-cu-diabet-zaharat-2016. Accessed 
10 April 2018  
32. Guía de práctica clínica para el diagnóstico, tratamiento y control de la diabetes 
mellitus tipo 2 en el primer nivel de atención [article online], 2016. Available from 
http://bvs.minsa.gob.pe/local/MINSA/3466.pdf. Accessed 4 December 2017 2017 
33. Stokes A, Berry KM, McHiza Z, et al. Prevalence and unmet need for diabetes 
care across the care continuum in a national sample of South African adults: 
Evidence from the SANHANES-1, 2011-2012. PLoS One 2017;12:e0184264 
34. Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a 
global perspective. Lancet Diabetes Endocrinol 2016;4:275-285 
35. Riza AL, Pearson F, Ugarte-Gil C, et al. Clinical management of concurrent 
diabetes and tuberculosis and the implications for patient services. Lancet Diabetes 
Endocrinol 2014;2:740-753 
36. Ewen M, Zweekhorst M, Regeer B, Laing R. Baseline assessment of WHO’s 
target for both availability and affordability of essential medicines to treat non-
communicable diseases. PLOS ONE 2017;12:e0171284 
 19 
37. Bazargani YT, de Boer A, Leufkens HGM, Mantel-Teeuwisse AK. Selection of 
Essential Medicines for Diabetes in Low and Middle Income Countries: A Survey of 
32 National Essential Medicines Lists. PLOS ONE 2014;9:e106072 
38. Glezeva N, Chisale M, McDonald K, Ledwidge M, Gallagher J, Watson CJ. 
Diabetes and complications of the heart in Sub-Saharan Africa: An urgent need for 
improved awareness, diagnostics and management. Diabetes Res Clin Pract 
2018;137:10-19 
39. Clarke PM, Glasziou P, Patel A, Chalmers J, Woodward M, Harrap SB, Salomon 
JA, on behalf of the ACG. Event rates, hospital utilization, and costs associated with 
major complications of diabetes: A multicountry comparative analysis. PLOS Med 
2010;7:e1000236 
40. Lee JD, Saravanan P, Varadhan L, Morrissey JR, Patel V. Quality of diabetes 
care worldwide and feasibility of implementation of the Alphabet Strategy: GAIA 
project (Global Alphabet Strategy Implementation Audit). BMC Health Serv Res 
2014;14:467 
41. Kane J, Landes M, Carroll C, Nolen A, Sodhi S. A systematic review of primary 
care models for non-communicable disease interventions in Sub-Saharan Africa. 
BMC Fam Pract 2017;18:46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20 
Table 1: General characteristics of patients with diabetes according to 
recruitment site 
 
CAD: coronary artery disease; DM: Diabetes mellitus; eGFR: estimated glomerular filtration rate mL/min/1.73 m2; 
IQR: Interquartile range; MI: myocardial infarction; n/a =not available 
* Denominator for proportions does not include the number not available.  
† Data available for a total of 1783 patients: 780 Indonesia; 379 Peru; 588 Romania; 36 South Africa.  
‡ Patients may be in more than one category   
 Total 
(n=2068) 
n (%) 
Indonesia 
(n=783) 
n (%) 
Peru 
(n=599) 
n (%) 
Romania 
(n=603) 
n (%) 
South Africa 
(n=83) 
n (%) 
Female sex 1301 (62.9) 500 (63.9) 426 (71.1) 321 (53.2) 54 (64.1) 
Age, median (IQR) 59 (52-66) 59 (53-65) 59 (52-67) 59 (51-66) 53 (47-60) 
Education      
<Primary/no formal education 687 (33.4) 235 (30.0) 304 (50.8) 84 (14.2) 61 (74.4) 
Secondary school completed 473 (23.0) 146 (18.6) 112 (18.7) 201 (33.9) 14 (17.1) 
High school completed  641 (31.2) 226 (28.9) 163 (27.3) 247 (41.7) 5 (6.1) 
College/university/post graduate  258 (12.5) 176 (22.5) 19 (3.2) 61 (10.3) 2 (2.4) 
n/a* 12 0 1 10 1 
Socio-economic status      
Q1: poorest 222 (10.9) 96 (12.4) 82 (13.7) 43 (7.3) 1 (1.2) 
Q2: poor 332 (16.2) 111 (14.4) 121 (20.2) 93 (15.7) 7 (8.6) 
Q3: middle income 378 (18.5) 121 (15.7) 126 (21.1) 119 (20.1) 12 (14.8) 
Q4: upper middle income  477 (23.3) 179 (23.2) 123 (20.6) 148 (25.0) 27 (33.3) 
Q5: richest 635 (31.1) 265 (34.3) 146 (24.4) 190 (32.0) 34 (42.0) 
n/a* 24 11 1 10 2 
Use of alcohol  660 (31.9) 14 (1.7) 288 (48.1) 338 (56.1) 21 (25.3) 
Duration of diabetes      
<1 year 388 (18.8) 138 (17.6) 126 (21.1) 122 (20.3) 2 (2.5) 
1-5 years 672 (32.6) 298 (38.1) 237 (39.6) 110 (18.3) 27 (33.3) 
6-15 years 704 (34.1) 280 (35.8) 139 (23.2) 249 (41.4) 36 (44.4) 
>15 years 299 (14.5) 67 (8.6) 96 (16.1) 120 (20.0) 16 (19.8) 
n/a* 5 0 1 2 2 
HbA1c,† Median % 
                IQR %  
8.7  
(7.0-10.7) 
8.3  
(6.7-10.2) 
7.7  
(6.2-10.1) 
9.5  
(8.1-11.3) 
10.4  
(9.0-12.0) 
              Median (IQR) mmol/mol 72 (53-93) 67 (50-88) 61 (44-87) 80 (65-100) 90 (75-108) 
HbA1c      
<7% (53 mmol/mol) 433 (24.3) 220 (28.2) 144 (38.0) 65 (11.1) 4 (11.1) 
7-9.9% (53-85 mmol/mol)   757 (42.5) 339 (43.5) 137 (36.2) 271 (46.1) 10 (27.8) 
≥10% (65 mmol/mol) 593 (33.3) 221 (28.3) 98 (25.9) 252 (42.9) 22 (61.1) 
n/a* 285 3 220 15 47 
Diabetes medication‡       
No medication  180 (8.7) 63 (8.1) 87 (14.5) 29 (4.8) 1 (1.2) 
Insulin  781 (37.8) 223 (28.5) 120 (20.0) 406 (67.3) 32 (38.6) 
Metformin 1295 (62.6) 431 (55.0) 391 (65.3) 398 (66.0) 75 (90.4) 
Other oral DM drugs 720 (34.8) 357 (45.6) 91 (15.2) 248 (41.1) 24 (28.9) 
Comorbidities and 
complications‡  
     
Infarct (CAD, angina, MI) 326 (15.8) 140 (17.9) 46 (7.7) 133 (22.1) 7 (8.4) 
Heart failure  14 (0.7) 13 (1.7) 1 (0.2) 0 (0.0) 0 (0.0) 
Cerebrovascular disease  7 (0.3) 0 (0.0) 3 (0.5) 0 (0.0) 4 (4.8) 
Peripheral vascular disease 27 (1.3) 20 (2.6) 0 (0.0) 6 (1.0) 1 (1.2) 
Kidney disease 31 (1.5) 21 (2.7) 7 (1.2) 3 (0.5) 0 (0.0) 
Eye problems attributable to DM 1043 (50.4) 272 (34.7) 463 (77.3) 258 (42.8) 50 (60.2) 
Renal Clearance       
eGFR ≥60 949 (81.1) 216 (73.5) 184 (82.9) 502 (83.3) 47 (92.2) 
eGFR 30-59 174 (14.9) 56 (19.0) 30 (13.5) 85 (14.1) 3 (5.9) 
eGFR <30 47 (4.0) 22 (7.5) 8 (3.6) 16 (2.6) 1 (1.9) 
n/a* 898 489 377 0 32 
Urine albumin/creatinine ratio       
<30 ug/mg 854 (60.2) 387 (50.0) n/a 422 (71.0) 45 (90.0) 
30-299 ug/mg 356 (25.1) 230 (29.7) n/a 121 (20.4) 5 (10.0) 
   ≥300 ug/mg 208 (14.7) 157 (20.3) n/a 51 (8.6) 0 (0.0) 
    n/a* 51 9  9 33 
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Table 2. Cardiovascular risk profile and medication management of patients 
according to recruitment site 
BMI: Body mass index (kg/m2); BP: Blood pressure; HDL: High density lipoprotein; LDL: Low density lipoprotein; 
WC: Waist circumference, n/a =not available   
* Body Mass Index (kg/m2) was classified as: 
 Underweight (<18.5) 
 Normal (18.5-22.9 Indonesia; 18.5-24.9 Peru, Romania, South Africa) 
 Overweight (23.0-24.9 Indonesia; 25.0-29.9 Peru, Romania, South Africa) 
 Obese (≥25.0 Indonesia; ≥30 Peru, Romania, South Africa) 
† Denominator for proportions does not include the number not available 
‡ Blood pressure classification according JNC VII: 
 Normal = systolic and diastolic <120/80 mmHg;  
 Pre-hypertension = systolic 120-139 or diastolic 80-89 mmHg;  
 Stage I hypertension = systolic 140-159 or diastolic 90-99 mmHg; 
 Stage II hypertension = systolic ≥160 or diastolic ≥100 mmHg.  
 Total 
(n=2068) 
n (%) 
Indonesia 
(n=783) 
n (%) 
Peru 
(n=599) 
n (%) 
Romania 
(n=603) 
n (%) 
South 
Africa 
(n=83) 
n (%) 
Body Mass Index (kg/m2)*      
Underweight 42 (2.0) 24 (3.1) 4 (0.7) 14 (2.4) 0 (0.0) 
Normal  503 (24.4) 191 (24.4) 186 (31.2) 111 (18.6) 15 (18.5) 
Overweight 577 (28.0) 149 (19.0) 210 (35.2) 188 (31.5) 30 (37.0) 
Obese 936 (45.5) 419 (53.5) 197 (33.0) 284 (47.6) 36 (44.4) 
n/a† 10 0 2 6 2 
Central Obesity      
Females  1099/1296 
(84.8) 
347/500  
(69.4) 
408/426 
(95.7) 
292/317 
(92.1) 
52/53  
(98.1) 
Males  476/759 
(62.7) 
108/283  
(38.2) 
131/173  
(75.7) 
217/275 
(78.9) 
20/28  
(71.4) 
BP classification: patients not on 
anti-hypertensives‡  
     
Normal  357 (26.3) 104 (17.8) 196 (42.2) 54 (19.7) 3 (8.6) 
Pre-hypertension  517 (38.1) 182 (31.2) 198 (42.7) 123 (44.9) 14 (40.0) 
Stage I hypertension   308 (22.7) 176 (30.1) 45 (9.7) 77 (28.1) 10 (28.6) 
Stage II hypertension   175 (12.9) 122 (20.9) 25 (5.4) 20 (7.3) 8 (22.9) 
BP classification: patients on 
anti-hypertensives‡ 
     
Normal  73 (10.3) 13 (6.5) 22 (16.3) 35 (10.6) 3 (6.3) 
Pre-hypertension  208 (29.3) 45 (22.6) 54 (40.0) 96 (29.2) 13 (28.1) 
Stage I hypertension   212 (29.8) 58 (29.2) 34 (25.2) 105 (31.9) 15 (31.3) 
Stage II hypertension   218 (30.7) 83 (41.7) 25 (18.5) 93 (28.3) 17 (35.4) 
Dyslipidemia (mg/dl): patients not 
on statins 
     
LDL ≥100 (2.6 mmol/l)  191/260 
(73.5) 
159/200  
(79.5) 
n/a 16/29  
(55.2) 
16/31  
(51.6) 
HDL ≤40 (male); ≤50 (female) 
(1 mmol/l (male); 1.3 (female))  
127/261 
(48.7) 
93/200 
 (46.5) 
n/a 15/28 
(53.6) 
19/33 
(57.6) 
Dyslipidemia (mg/dL): patients on 
statins 
     
LDL ≥100 (2.6 mmol/l) 76/107 
(71.0) 
59/66 
(89.4) 
n/a 11/24 
(45.8) 
6/17  
(35.3) 
HDL ≤40 (male); ≤50(female)  
(1 mmol/l (male); 1.3 (female)) 
65/107 
(60.7) 
29/66 
(43.9) 
n/a 21/24 
(87.5) 
15/17 
(88.2) 
Smoking status      
Current 269 (13.0) 112 (14.3) 34 (5.7) 93 (15.5) 30 (36.6) 
Past 630 (30.5) 223 (28.5) 221 (37.0) 172 (28.6) 14 (17.1) 
Never 1165 (56.4) 448 (57.2) 343 (57.4) 336 (55.9) 38 (46.3) 
n/a† 4 0 1 2 1 
Anti-hypertensive drugs 711 (34.4) 199 (25.4) 135 (22.5) 329 (54.6) 48 (57.8) 
Lipid-lowering drugs (statins) 407 (19.7) 146 (18.6) 36 (6.0) 201 (33.3) 24 (28.9) 
Anti-platelet drugs (aspirin) 249 (12.0) 47 (6.0) 53 (8.9) 121 (20.1) 28 (33.7) 
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Table 3. Treatment indication and actual treatment with insulin, 
antihypertensive, antiplatelet, and lipid-lowering medication according to 
recruitment site 
 
 Total 
n/N (%) 
Indonesia 
n/N (%) 
Peru 
n/N (%) 
Romania 
n/N (%) 
South 
Africa 
n/N (%) 
HbA1c ≥10 (86 mmol/mol)*  593/1783 
(33.3) 
221/780 
(28.3) 
98/379 
(25.9) 
252/588 
(42.9) 
22/36 
(61.1) 
Patients with HbA1c≥10 (86 
mmol/mol) receiving insulin 
325/593 
(54.8) 
70/221 
(31.7) 
40/98 
(40.8) 
199/252 
(80.0) 
16/22 
(72.7) 
      
Hypertension†  913/2068 
(44.1) 
439/783 
(56.1) 
129/599 
(21.5) 
295/603 
(48.9) 
50/83 
(59.5) 
Patients with hypertension  
taking anti-hypertensives  
430/913 
(47.1) 
141/439 
(32.1) 
59/129 
(45.7) 
198/295 
(67.1) 
32/50 
(64.0) 
      
Cardiovascular complications‡  326/2068 
(15.8) 
140/783 
(17.9) 
46/599 
(7.7) 
133/603 
(22.1) 
7/83 
(8.4) 
Patients with cardiovascular 
complications taking aspirin 
98/326 
(30.0) 
28/140 
(20.0) 
21/46 
(45.6) 
43/133 
(32.3) 
6/7 
(85.7) 
      
LDL ≥100mg/dL (2.6 mmol/l)/§ 267/367 
(72.8) 
218/266 
(82.0) 
n/a 27/53 
(50.9) 
22/48 
(45.8) 
Patients with LDL ≥100mg/dL 
         (2.6 mmol/l) taking statins  
76/267 
(28.5) 
59/218 
(27.1) 
n/a 11/27 
(40.7) 
6/22 
(27.3) 
* Of those with a reported HbA1c. † Systolic blood pressure (BP) ≥140 mm Hg; diastolic BP ≥90 
‡ Cardiovascular complications: Includes patients categorized with coronary artery disease, angina or 
myocardial infarction. § Of those with a reported low-density lipoprotein (LDL) 
n/a: not available  
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Table 4. Patients receiving insulin, antihypertensives, and lipid-lowering 
medication and those who have reached the treatment target according to 
recruitment site 
 
 Total 
n/N (%) 
 
Indonesia 
n/N (%) 
Peru 
n/N (%) 
Romania 
n/N (%) 
South 
Africa 
n/N (%) 
Patients on insulin 780/2068 
(37.7) 
223/783 
(28.5) 
120/599 
(20.0) 
405/603 
(67.2) 
32/83 
(38.6) 
Patients on insulin with  
a recorded HbA1c <7%  
(53 mmol/mol) 
77/780 
(8.0) 
41/223 
(18.4) 
15/120 
(12.5) 
20/405 
(4.9) 
1/32 
(3.1) 
      
Patients on antihypertensives 711/2068 
(34.4) 
199/783 
(25.4) 
135/599 
(22.5) 
329/603 
(54.6) 
48/83 
(57.8) 
Patients on antihypertensives 
with BP systolic <140  
& diastolic <90  
281/711 
(39.5) 
58/199 
(29.1) 
76/135 
(56.3) 
131/329 
(39.8) 
16/48 
(33.3) 
      
Patients on statins 407/2068 
(19.7) 
146/783 
(18.6) 
36/599 
(6.0) 
201/603 
(33.3) 
24/83 
(28.9) 
Patients on statins  
with LDL <100 mg/dL (2.6 
mmol/l) 
31/371 
(8.4) 
7/146 
(4.8) 
n/a 13/201 
(6.5) 
11/24 
(45.8) 
 
 
